Related Experiment Video

Updated: Aug 3, 2025

The Use of Reverse Phase Protein Arrays RPPA to Explore Protein Expression Variation within Individual Renal Cell Cancers
12:22

The Use of Reverse Phase Protein Arrays RPPA to Explore Protein Expression Variation within Individual Renal Cell Cancers

Published on: January 22, 2013

33.7K

Research of targeted therapy for renal cancer from 2006 to 2022: a bibliometric and visualized analysis

Yuanqing Gou1, Yongxin Fu1, Yadong Li1

  • 1Department of Urology Surgery, The Second Affiliated Hospital of Chongqing Medical University, Chongqing, China.

Translational Andrology and Urology
|April 10, 2023
PubMed
Abstract

Insights

This bibliometric analysis reveals a steady growth in research on targeted therapy for renal cancer. Key trends include hypoxia-inducing factor-1, drug resistance, and therapeutic targets, with the US leading contributions.

Area of Science:

  • Oncology
  • Pharmacology
  • Medical Research

Background:

  • Renal cancer (RC) research has seen significant advancements.
  • Targeted therapy (TT) has emerged as a crucial treatment modality.

Purpose of the Study:

  • To analyze research progress and development trends in targeted therapy for renal cancer (RC) between 2006 and 2022.
  • To identify key research hotspots and future directions in the field.

Main Methods:

  • Bibliometric analysis of publications from the Web of Science Core Collection.
  • Utilized VOSviewer for visual analysis of authors, journals, subjects, years, and institutions.
  • Keywords: "renal cancer", "kidney neoplasms", "kidney cancer", "targeted therapy".

Main Results:

  • A total of 1,136 studies were identified.
  • The United States led in publications (n=366).
  • Top journals include Journal of Clinical Oncology, Annals of Oncology, and European Urology.

Conclusions:

  • This is the first bibliometric analysis of targeted therapy for renal cancer.
  • A steady annual growth in publications indicates increasing research interest.
  • Research hotspots include hypoxia-inducing factor-1, drug resistance, and therapeutic targets.
Keywords:
Targeted therapyVOSviewerbibliometric analysisrenal cancer

More Related Videos

A Syngeneic Mouse Model of Metastatic Renal Cell Carcinoma for Quantitative and Longitudinal Assessment of Preclinical Therapies06:38

A Syngeneic Mouse Model of Metastatic Renal Cell Carcinoma for Quantitative and Longitudinal Assessment of Preclinical Therapies

Published on: April 12, 2017

13.7K
Global and Current Research Trends of Single-Cell Sequencing in Cancer: A Bibliometric and Visualization Study07:50

Global and Current Research Trends of Single-Cell Sequencing in Cancer: A Bibliometric and Visualization Study

Published on: April 18, 2025

341

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.7K
Cancer Therapies02:49

Cancer Therapies

Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
7.8K
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
5.0K
Cancer Survival Analysis01:21

Cancer Survival Analysis

Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...
406
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
4.8K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
3.8K